The Maryland-based biotech is eliminating 80% of its team after the FDA determined that the company's investigational acute myeloid leukemia treatment uproleselan requires another clinical trial to continue forward on the path to possible approval.
https://www.businesswire.com/news/home/20240725473857/en/GlycoMimetics-Announces-Strategic-Review-and-Corporate-Restructuring-Plan